AstraZeneca (AZN) Tops Q1 EPS by 5c

AstraZeneca (NYSE: AZN) reported Q1 EPS of $0.89, $0.05 better than the analyst estimate of $0.84. Revenue for the quarter came in at $5.49 billion versus the consensus estimate of $5.38 billion.

GUIDANCE:

AstraZeneca sees FY2019 EPS of $3.50-$3.70, versus the consensus of $3.50.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
• Prenetics Global (PRE) Tops Q2 EPS by 18c
• Taylor Devices (TAYD) Misses Q4 EPS by 31c